Cite
HARVARD Citation
Mo, Z. et al. (2022). Safety and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus type 6/11 vaccine: A dose-escalation, randomized, double-blind, placebo-controlled phase 1 trial. Human vaccines & immunotherapeutics. 18 (6), p. . [Online].